Univest
Univest
  • Markets

Glaxosmithkline Pharmaceuticals Ltd. (GLAXO): GlaxoSmithKline Pharma Share Price Rises 2.27% to Rs 2,709.00 Today

  • September 7, 2026
  • Posted by: Kunal Singla
  • Category: News
No Comments
GlaxoSmithKline Pharma Share Price
Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) share price rose to Rs 2,709 today, up 2.27% from the previous close. Market cap was Rs 45,223.79 crore.

GlaxoSmithKline Pharma Share Price stood at Rs 2,709.00 as of 17 November 2026 at 2:22 PM IST, up Rs 60.00 or 2.27% from the previous close of Rs 2,649.00. The Pharmaceuticals & Drugs company has a market capitalisation of Rs 45,223.79 crore, according to latest Univest data.

The GlaxoSmithKline Pharma Share Price rise comes after an open at Rs 2,680.00, with the stock now trading at its day high of Rs 2,709.00. Univest data confirms the move itself, though no company-specific trigger has been identified.

Table of Contents

Toggle
  • GlaxoSmithKline Pharma Share Price Today: Price Action Analysis
  • Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) Fundamental Analysis
  • Sector and Industry Context
  • Peer Comparison
  • Why Investors Are Watching GlaxoSmithKline Pharma
  • About GlaxoSmithKline Pharma
  • Frequently Asked Questions
    • How much has the GlaxoSmithKline Pharma share price risen today?
    • What is the day high and day low of the GlaxoSmithKline Pharma share price?
    • What is the market capitalisation of GlaxoSmithKline Pharma?
    • What is the P/E ratio behind the GlaxoSmithKline Pharma share price?
    • What are the ROE and ROCE of GlaxoSmithKline Pharma?
    • What are the EPS and book value of GlaxoSmithKline Pharma?
    • What is the dividend yield of GlaxoSmithKline Pharma?
  • Track GlaxoSmithKline Pharma Share Price on Univest

GlaxoSmithKline Pharma Share Price Today: Price Action Analysis

Metric Value
Current Price Rs 2,709
Previous Close Rs 2,649
Today's Move Rs 60 (+2.27%)
Open Rs 2,680
High Rs 2,709
Low Rs 2,664.25
Market Capitalisation Rs 45,223.79 crore
Market Cap Category Large Cap

Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) rose to Rs 2,709 from the previous close of Rs 2,649, a move of Rs 60 or 2.27%. The stock opened at Rs 2,680, reached a high of Rs 2,709, recorded a low of Rs 2,664.25.

The GlaxoSmithKline Pharma Share Price Today is Rs 2,709.00, a gain of Rs 60.00 or 2.27% over the previous close of Rs 2,649.00. The stock opened at Rs 2,680.00 and has traded between Rs 2,664.25 and Rs 2,709.00 as of 2:22 PM IST on 17 November 2026.

The opening price was Rs 31.00 above the previous close, and the day low of Rs 2,664.25 sits Rs 15.75 below the open. The current price matches the day high of Rs 2,709.00 and is Rs 44.75 above the day low, so the GlaxoSmithKline Pharma Share Price is at the top of its range for the session so far.

Market capitalisation stands at Rs 45,223.79 crore at the current price. The next sections look at what the GlaxoSmithKline Pharma fundamental analysis says about earnings, returns, book value and dividend yield.

Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) Fundamental Analysis

Metric Value
Market Capitalisation Rs 45,223.79 crore
P/E Ratio 39.14x
P/B Ratio 23.86x
ROE 48.76%
ROCE 66.79%
EPS Rs 67.68
Book Value Per Share Rs 111.04
Dividend Yield 2.15%

Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) fundamental metrics show P/E 39.14x, P/B 23.86x, ROE 48.76%, ROCE 66.79%. Read together, these ratios describe the company’s position rather than a recommendation.

Glaxosmithkline Pharmaceuticals Ltd. has a market capitalisation of Rs 45,223.79 crore and falls in the Large Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 39.14x, P/B at 23.86x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 48.76% and ROCE of 66.79%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 67.68, book value per share of Rs 111.04, dividend yield of 2.15%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 30.46x, median ROE of 11.33%, median ROCE of 13.1%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.

Sector and Industry Context

Metric Value
Sector Healthcare
Industry Pharmaceuticals & Drugs
Benchmark Scope same industry
Company P/E Ratio 39.14x
Benchmark Median P/E 30.46x
Benchmark Average P/E 52.1x
Benchmark P/E Range 2.82x to 1,227.27x
Company P/B Ratio 23.86x
Benchmark Median P/B 2.92x
Company ROE 48.76%
Benchmark Median ROE 11.33%
Company ROCE 66.79%
Benchmark Median ROCE 13.1%
Company Market Capitalisation Rs 45,223.79 crore
Benchmark Median Market Cap Rs 760.34 crore

Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.

Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) has a P/E ratio of 39.14x, which is above the benchmark median of 30.46x, a difference of +28.5%. The P/E comparison frames valuation; it is not a signal to buy or sell.

Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) has a ROE of 48.76%, which is above the benchmark median of 11.33%, a difference of +330.36%. Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) has a ROCE of 66.79%, which is above the benchmark median of 13.1%, a difference of +409.85%.

Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.

Peer Comparison

Company Symbol Market Cap (Cr) P/E P/B ROE (%) ROCE (%)
Sun Pharmaceutical Industries Ltd. SUNPHARMA 4,51,290.91 40.85 5.02 14.85 19.11
Divi's Laboratories Ltd. DIVISLAB 3,05,014.11 87.71 16.39 16.19 21.51
Torrent Pharmaceuticals Ltd. TORNTPHARM 1,77,333.2 83.99 9.71 26.76 19.27
Laurus Labs Ltd. LAURUSLABS 1,30,755.56 89.4 19.77 18.31 18.2
Zydus Lifesciences Ltd. ZYDUSLIFE 1,18,802.71 28.37 4.26 19.69 21.39

Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) has a P/E ratio of 39.14x compared with the displayed peer median of 83.99x. Peer multiples give relative context only, not a buy or sell view. Its ROE of 48.76% compares with a peer median of 18.31% across the companies shown in the table. ROCE stood at 66.79% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) has a market capitalisation of Rs 45,223.79 crore. All 5 peers shown have a larger market capitalisation.

Why Investors Are Watching GlaxoSmithKline Pharma

  • The GlaxoSmithKline Pharma Share Price rose 2.27% to Rs 2,709.00 against a previous close of Rs 2,649.00.
  • The day range of Rs 2,664.25 to Rs 2,709.00 places the current price at the top of the session’s range.
  • ROE of 48.76% and ROCE of 66.79% sit above both the Pharmaceuticals & Drugs industry medians of 11.33% and 13.10% and all five peers.
  • The GlaxoSmithKline Pharma Share Price carries a P/E ratio of 39.14, above the industry median of 30.46, with a dividend yield of 2.15%.
  • Market capitalisation of Rs 45,223.79 crore is above the industry median of Rs 760.34 crore and the average of Rs 14,899.39 crore, and below all five peers.

About GlaxoSmithKline Pharma

GlaxoSmithKline Pharma Ltd., formally Glaxosmithkline Pharmaceuticals Ltd., trades under the symbol GLAXO and operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. Its business is benchmarked against an industry group of 200 companies, with peers such as Sun Pharmaceutical, Divi’s Laboratories, Torrent Pharmaceuticals, Laurus Labs and Zydus Lifesciences.

With a market capitalisation of Rs 45,223.79 crore, EPS of Rs 67.68 and book value of Rs 111.04 per share, it sits above both the median and the average company in its industry group on market capitalisation.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).

Frequently Asked Questions

How much has the GlaxoSmithKline Pharma share price risen today?

Ans. The GlaxoSmithKline Pharma Share Price has risen Rs 60.00, or 2.27%, from the previous close of Rs 2,649.00 to Rs 2,709.00. The stock opened at Rs 2,680.00 and has traded between Rs 2,664.25 and Rs 2,709.00.

What is the day high and day low of the GlaxoSmithKline Pharma share price?

Ans. The GlaxoSmithKline Pharma Share Price touched a day high of Rs 2,709.00 and a day low of Rs 2,664.25 so far today. The current price matches the high and sits Rs 44.75 above the low.

What is the market capitalisation of GlaxoSmithKline Pharma?

Ans. GlaxoSmithKline Pharma has a market capitalisation of Rs 45,223.79 crore at the current GlaxoSmithKline Pharma Share Price of Rs 2,709.00. The industry benchmark has a median of Rs 760.34 crore and an average of Rs 14,899.39 crore.

What is the P/E ratio behind the GlaxoSmithKline Pharma share price?

Ans. GlaxoSmithKline Pharma has a P/E ratio of 39.14 and a P/B ratio of 23.86. The Pharmaceuticals & Drugs industry shows a median P/E of 30.46 and an average of 52.10, while the median P/B is 2.92.

What are the ROE and ROCE of GlaxoSmithKline Pharma?

Ans. GlaxoSmithKline Pharma reports ROE of 48.76% and ROCE of 66.79%. The industry medians are 11.33% for ROE and 13.10% for ROCE, so both ratios sit above the median benchmark and above all five listed peers.

What are the EPS and book value of GlaxoSmithKline Pharma?

Ans. GlaxoSmithKline Pharma has earnings per share of Rs 67.68 and a book value of Rs 111.04 per share. EPS shows the earnings attributable to each share, while book value shows the accounting net worth behind each share.

What is the dividend yield of GlaxoSmithKline Pharma?

Ans. The latest Univest figures show a dividend yield of 2.15% for GlaxoSmithKline Pharma. Dividend yield is historical data relative to the current price of Rs 2,709.00 and does not indicate what any future payout will be.

Track GlaxoSmithKline Pharma Share Price on Univest

Use Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.

Users can track the live GlaxoSmithKline Pharma Share Price, fundamental ratios, 52-week levels and market insights on Univest, along with the latest GlaxoSmithKline Pharma stock news and market updates. Univest also lists the sector benchmarks and peer figures used in this GlaxoSmithKline Pharma stock analysis, so each ratio can be read in context before any decision is taken independently.



Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply